- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial
13 September 2016 • Author: Niamh Louise Marriott, Digital Content Producer
Under Ergomed’s co-development agreement with Ferrer, the Phase IIa clinical trial is a double-blind, randomised, placebo-controlled cross-over, dose finding study of two oral doses of lorediplon in adult patients with insomnia disorder.
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients with insomnia disorder.
The recruitment target of at least 130 patients has been met from 11 clinical sites across three European countries. The clinical trial is expected to complete in autumn of 2016 with the final results announced around the end of the year.
Ergomed’s CEO, Dr Miroslav Reljanovic, said, “The completion of patient recruitment in the Phase IIa study in insomnia marks another important step in the clinical development of lorediplon for the treatment of insomnia. Lorediplon previously demonstrated – in a phase advanced model of insomnia – a potential best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to the market leader zolpidem. This would make a marked improvement in the lives of patients suffering from this disorder. We look forward to reporting the results around the end of the year.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics